Hussain Kosar, Xavier Anil
General Medicine, Goulburn Valley Health, Shepparton, Victoria, Australia
Nephrology and General Medicine, Goulburn Valley Health, Shepparton, Victoria, Australia.
BMJ Case Rep. 2019 Oct 9;12(10):e229244. doi: 10.1136/bcr-2019-229244.
We describe the case of a 76-year-old man who presented with bilateral lower limb weakness associated with decreased urine output. His initial blood results showed acute kidney injury (AKI) stage 3 with substantially raised serum creatine kinase concentration of 37 950 IU/L (normal range <171 U/L). He had been on high-dose rosuvastatin for 4 years with a recent brand change occurring 1 week prior to onset of symptoms. There was no history of pre-existing neuromuscular disease. Statin-related rhabdomyolysis was suspected and rosuvastatin was withheld. His muscle strength gradually improved. He required haemodialysis for 10 weeks. He was discharged home after a complicated course of hospitalisation. His renal function improved and he became dialysis-independent; however, he was left with residual chronic kidney disease.
我们描述了一名76岁男性的病例，该患者出现双侧下肢无力并伴有尿量减少。其初始血液检查结果显示为急性肾损伤（AKI）3期，血清肌酸激酶浓度大幅升高至37950 IU/L（正常范围<171 U/L）。他服用高剂量瑞舒伐他汀已4年，在症状出现前1周最近更换了品牌。既往无神经肌肉疾病史。怀疑为他汀类药物相关的横纹肌溶解症，停用了瑞舒伐他汀。他的肌肉力量逐渐改善。他需要进行10周的血液透析。在经历了复杂的住院过程后，他出院回家。他的肾功能有所改善，不再依赖透析；然而，他仍遗留有残余慢性肾脏病。
